Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia

Koichi Takahashi, Naveen Pemmaraju, Paolo Strati, Graciela Nogueras-Gonzalez, Jing Ning, Carlos Bueso-Ramos, Rajyalakshmi Luthra, Sherry Pierce, Jorge Cortes, Hagop Kantarjian, Guillermo Garcia-Manero

Research output: Contribution to journalArticlepeer-review

47 Scopus citations

Abstract

We sought to describe the clinical features and outcomes of therapy-related chronic myelomonocytic leukemia (t-CMML) and compare with those of de novo CMML. We identified 358 CMML patients, of whom 39 (11%) had t-CMML. Although the groups had similar demographic, hematologic, and molecular alteration profiles, the proportion of patients with intermediate or high CMML-specific cytogenetic risk in the t-CMML was significantly higher than that in the de novo CMML (P =.011). The median latency to develop t-CMML was 6 years. The median overall and leukemia-free survival duration of the t-CMML were shorter than those of the de novo CMML; however, t-CMML itself was not prognostic after adjusting for the effects of other covariates including cytogenetics. These results suggest that compared with de novo CMML, t-CMML is associated with more high-risk cytogenetics that manifest as poor outcomes. We propose that t-CMML be recognized as one of the therapy-related myeloid neoplasms.

Original languageEnglish (US)
Pages (from-to)2807-2811
Number of pages5
JournalBlood
Volume122
Issue number16
DOIs
StatePublished - Oct 17 2013
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia'. Together they form a unique fingerprint.

Cite this